Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The FDA drug safety surveillance program: adverse event reporting trends.

Literature DB >> 21444854

The FDA drug safety surveillance program: adverse event reporting trends.

Sheila Weiss-Smith¹, Gaurav Deshpande, Stephanie Chung, Victor Gogolak.

Abstract

Mesh：

Year: 2011 PMID： 21444854 DOI： 10.1001/archinternmed.2011.89

Source DB: PubMed Journal: Arch Intern Med ISSN： 0003-9926

Keyword Cloud
Cited

× No keyword cloud information.

24 in total

1. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.

Authors: Kenneth Tong; Jean Paul Nicandro; Reshma Shringarpure; Emil Chuang; Lin Chang
Journal: Therap Adv Gastroenterol Date: 2013-09 Impact factor: 4.409

2. Publisher’s Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction.

Authors: Andrew D Rouillard; Zichen Wang; Avi Ma'ayan
Journal: Comput Biol Chem Date: 2015-10 Impact factor: 2.877

Review 3. Translational bioinformatics embraces big data.

Authors: N H Shah
Journal: Yearb Med Inform Date: 2012

4. Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data.

Authors: Pankdeep Chhabra; Xing Chen; Sheila R Weiss
Journal: Drug Saf Date: 2013-11 Impact factor: 5.606

5. Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual.

Authors: Taliser R Avery; Martin Kulldorff; Yury Vilk; Lingling Li; T Craig Cheetham; Sascha Dublin; Robert L Davis; Liyan Liu; Lisa Herrinton; Jeffrey S Brown
Journal: Pharmacoepidemiol Drug Saf Date: 2013-02-12 Impact factor: 2.890

The FDA drug safety surveillance program: adverse event reporting trends.

1. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.

2. Publisher’s Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction.

Review 3. Translational bioinformatics embraces big data.

4. Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data.

5. Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual.

6. Lean Big Data integration in systems biology and systems pharmacology.

7. The coming age of data-driven medicine: translational bioinformatics' next frontier.

Review 8. Data mining of the public version of the FDA Adverse Event Reporting System.

9. Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes.

10. Using temporal patterns in medical records to discern adverse drug events from indications.